$1.82 Billion is the total value of Bellevue Group AG's 138 reported holdings in Q1 2019. The portfolio turnover from Q4 2018 to Q1 2019 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CI | New | CIGNA CORP NEW | $26,641,000 | – | 165,657 | +100.0% | 1.47% | – |
| AVDR | New | AVEDRO INC | $9,203,000 | – | 750,000 | +100.0% | 0.51% | – |
| SWAV | New | SHOCKWAVE MED INC | $3,347,000 | – | 100,000 | +100.0% | 0.18% | – |
| SYNH | New | SYNEOS HEALTH INCcl a | $2,443,000 | – | 47,200 | +100.0% | 0.13% | – |
| ASND | New | ASCENDIS PHARMA A Ssponsored adr | $2,142,000 | – | 18,200 | +100.0% | 0.12% | – |
| FOLD | New | AMICUS THERAPEUTICS INC | $2,040,000 | – | 150,000 | +100.0% | 0.11% | – |
| PFE | New | PFIZER INC | $1,699,000 | – | 40,000 | +100.0% | 0.09% | – |
| LABD | New | DIREXION SHS ETF TRdaily s&p biotec | $1,380,000 | – | 75,000 | +100.0% | 0.08% | – |
| RDUS | New | RADIUS HEALTH INC | $1,178,000 | – | 59,100 | +100.0% | 0.06% | – |
| ARRY | New | ARRAY BIOPHARMA INC | $1,175,000 | – | 48,200 | +100.0% | 0.06% | – |
| BNFT | New | BENEFITFOCUS INC | $1,138,000 | – | 22,979 | +100.0% | 0.06% | – |
| ZLAB | New | ZAI LAB LTDadr | $885,000 | – | 30,000 | +100.0% | 0.05% | – |
| MDCO | New | MEDICINES CO | $811,000 | – | 29,000 | +100.0% | 0.04% | – |
| PBYI | New | PUMA BIOTECHNOLOGY INC | $663,000 | – | 17,100 | +100.0% | 0.04% | – |
| KURA | New | KURA ONCOLOGY INC | $486,000 | – | 29,300 | +100.0% | 0.03% | – |
| GILD | New | GILEAD SCIENCES INCcall | $174,000 | – | 600 | +100.0% | 0.01% | – |
| GLPG | New | GALAPAGOS NVput | $23,000 | – | 190 | +100.0% | 0.00% | – |
| ABBV | New | ABBVIE INCput | $9,000 | – | 200 | +100.0% | 0.00% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Bellevue Asset Management AG #1
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| IONIS PHARMACEUTICALS INC | 31 | Q3 2023 | 9.3% |
| Vertex Pharmaceuticals Incorporated | 31 | Q3 2023 | 5.9% |
| NEUROCRINE BIOSCIENCES INC | 31 | Q3 2023 | 5.7% |
| Incyte Corporation | 31 | Q3 2023 | 5.4% |
| INTUITIVE SURGICAL INC | 31 | Q3 2023 | 4.7% |
| ABBOTT LABS | 31 | Q3 2023 | 4.6% |
| ELEVANCE HEALTH INC | 31 | Q3 2023 | 4.3% |
| UnitedHealth Group Incorporated | 31 | Q3 2023 | 3.6% |
| ALNYLAM PHARMACEUTICALS INC | 31 | Q3 2023 | 3.7% |
| Boston Scientific Corporation | 31 | Q3 2023 | 2.5% |
View Bellevue Group AG's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| SC 13G | 2023-02-14 |
| SC 13G | 2023-02-14 |
| 13F-HR | 2022-11-14 |
View Bellevue Group AG's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.